Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aurobindo Pharma
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Aurobindo's Eugia tallies a 5th Form 483 in less than a year
May 14, 2024 9:40am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
Aurobindo's Eugia issues recall of muscle relaxant
Apr 2, 2024 8:40am
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am
After a pause, Aurobindo resumes drug shipments from India plant
Mar 13, 2024 3:40pm